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Perspectives
Norma Frizzell* and John W. Baynes
Chelation therapy for the management of diabetic 
complications: a hypothesis and a proposal 
for clinical laboratory assessment of metal ion 
homeostasis in plasma
Abstract: In a recent article, we presented the  hypothesis 
that decompartmentalized metal ions are a major con-
tributor to the development of diabetic complications 
and supported the use of chelation therapy for the treat-
ment of diabetic complications [Nagai R, Murray DB, Metz 
TO, Baynes JW. Chelation: a fundamental mechanism of 
action of AGE inhibitors, AGE breakers, and other inhibi-
tors of diabetes complications. Diabetes 2012;61:549–59]. 
Evidence in support of this hypothesis included the obser-
vation that many drugs used in the treatment of diabetes 
are chelators, that advanced glycation end product (AGE) 
inhibitors and AGE breakers lack carbonyl-trapping or 
AGE-breaker activity but are potent chelators, and that 
simple copper chelators inhibit vascular pathology in 
diabetes and aging. In the present article, we extend this 
hypothesis, proposing the interplay between copper and 
iron in the development of pathology in diabetes and 
other chronic age-related diseases, including atheroscle-
rosis and neurodegenerative diseases. We also discuss the 
need and provide a framework for the development of a 
clinical laboratory test to assess plasma autoxidative cata-
lytic activity and transition metal homeostasis in vivo.
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Introduction: chelation therapy 
for diabetic complications
Advanced glycation end products (AGE) accumulate in 
long-lived tissue proteins with age and at an accelerated 
rate in diabetes and other chronic inflammatory diseases 
[1, 2], including atherosclerosis and neurodegenerative 
diseases. The increase in AGEs develops in parallel with 
other chemical modifications of proteins, including 
advanced lipoxidation end products (ALE) and protein 
oxidation products (PrOP) [3, 4]. Tissue damage accrues 
not only because of protein chemical modification and 
cross-linking reactions but also because of inflammatory 
processes initiated by the interaction of modified proteins 
with the receptor for AGE as well as scavenger and toll-like 
receptors [5–7]. Metal-catalyzed autoxidation reactions, 
i.e., oxidation by molecular oxygen, participate in the for-
mation of ALEs, PrOPs, and most AGEs, supporting the 
close relationship between oxidative stress and age- and 
disease-related chemical modification of proteins.
Protein carbonyls are intermediates in the forma-
tion of AGEs, ALEs, and PrOPs, and AGE inhibitors such 
as pyridoxamine actually inhibit the formation of all 
three classes of chemical modifications of protein [8–10]. 
However, in a recent Perspectives article in the journal 
Diabetes [11], we made the following observations.
 – There is no evidence that AGE inhibitors actually trap 
carbonyl or dicarbonyl compounds in vivo or that 
dicarbonyl cross-links, the putative targets of AGE 
breakers, actually exist in vivo.
 – Chelation is the common mechanism of action of both 
AGE inhibitors and breakers. Indeed, LR compounds, 
which have no nucleophilic functional groups with 
potential carbonyl-trapping activity, are both AGE 
inhibitors and AGE breakers and have strong chelating 
activity [12, 13].
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 – Decompartmentalized copper and iron contribute to 
the development of diabetic complications because 
these metals catalyze nonenzymatic autoxidation 
reactions, which are involved in the formation of 
AGEs, ALEs, and PrOPs.
 – Drugs that are commonly used in the management of 
diabetes, including angiotensin-converting enzyme 
inhibitors (ACEi), angiotensin-receptor blockers 
(ARB), other antihypertensive agents (including 
hydralazine and thiazides), and aldose reductase 
inhibitors (ARI) are potent chelating agents.
 – Consistent with the argument that antidiabetic 
drugs act as chelators, the copper chelator 
triethylenetetramine (trientine, TETA) inhibits 
nephropathy in rodent models of diabetes and also 
reverses vascular disease in type 2 diabetic animal 
models and in diabetic patients [14, 15].
Based on these observations, we concluded that chronic 
chelation therapy deserves serious consideration as a 
clinical tool for the prevention and treatment of diabetic 
complications. Notably, this therapeutic regimen is dis-
tinct from that using intravenous infusion of strong che-
lators, such as ethylenediaminetetraacetic acid (EDTA), 
which was recently evaluated in the Trial to Assess Chela-
tion Therapy (TACT), sponsored by the National Center 
for Complementary and Alternative Medicine and the 
National Heart Lung and Blood Institute. The preliminary 
results of the TACT study, suggesting a benefit for diabetic 
subjects, were released at the 2012 meeting of the Ameri-
can Heart Association and, although still under peer 
review, have stirred some controversy [16].
Although not stated specifically, it is implicit in the 
above discussion that there is limited clinical potential for 
AGE inhibitors or breakers per se in the treatment of dia-
betic complications; most diabetic patients are already at 
least partially chelated by an armamentarium of alterna-
tive drug therapies, including ACEIs, ARBs, other antihy-
pertensives, and ARIs [11] as well as metformin [17]. The 
fact that AGE inhibitors and breakers are simply chelators 
may explain why, more than 25 years since the description 
of the original AGE inhibitor, aminoguanidine [18], and 
more than 15  years since the description of the original 
AGE breaker, phenylthiazolium bromide [19], and despite 
the introduction of less toxic and more stable AGE inhibi-
tors and breakers since that time [11], not one of these 
compounds has yet found a place in the clinical toolbox 
for management of diabetic complications. Although 
there is strong and incontrovertible evidence that AGE 
inhibitors and breakers are effective in animal models, 
except in rare cases, these animals, unlike their human 
counterparts, are not being treated simultaneously with 
other drugs. There are also several studies reporting that 
ACEIs and ARBs alone inhibit AGE formation and that in 
those instances in which animals are treated with ACEIs 
and ARBs, AGE inhibitors or breakers provide marginal 
additional benefit [11]. There is a growing consensus that 
many different types of drugs used for the treatment of 
diabetic complications have common downstream effects, 
including inhibition of inflammation and stimulation of 
antioxidant defenses, modification of lipid profiles, and 
inhibition of AGE formation [20, 21]. Chelation stands out 
as the most likely, shared mechanism of action of these 
drugs. Chelators inhibit the metal-catalyzed production of 
reactive oxygen species (ROS), thereby inhibiting chemi-
cal damage to proteins and subsequent proinflammatory 
cascades.
Copper and iron in chronic disease
The formation of AGEs, ALEs, and PrOPs is a manifes-
tation of oxidative stress and autoxidative damage to 
biomolecules, catalyzed in biological systems by tran-
sition metals such as copper and/or iron. These metals 
are “redox-active”, cycling between the oxidized and the 
reduced state during the generation of ROS by Fenton 
and Haber-Weiss chemistry. In experiments with the 
copper chelator trientine, a drug commonly used for 
treatment of Wilson disease, a copper storage disease, 
Cooper [14, 15] demonstrated that there is more chelat-
able (loosely bound) copper in the heart of diabetic rats 
and that TETA promotes increased secretion of copper in 
urine of diabetic rats and humans, compared with non-
diabetic controls. In animal models, TETA caused an 
increase in vascular elasticity and a decrease in inflam-
matory biomarkers, and during a 6-month clinical study, 
trientine inhibited increases in left ventricular mass in 
type 2 diabetic patients. TETA also inhibited a decrease 
in aortic elasticity in the streptozotocin-diabetic rat and 
normalized several biomarkers of inflammation and fibro-
sis. Baynes and Murray [22] showed that TETA preserved 
cardiovascular function in the Zucker obese rat, whereas 
Nagai et al. [23] demonstrated that citric acid, which is a 
less specific chelator of divalent cations, protected against 
nephropathy and inhibited AGE formation in the lens of 
streptozotocin-diabetic rats. In a recent study, Frei and 
colleagues [24] demonstrated that a chemically unrelated 
copper chelator, tetrathiomolybdate (TTM), also protected 
against vascular inflammation and atherogenesis in the 
apolipoprotein E-deficient, atherosclerosis-prone mouse. 
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Although not studied in detail, it is likely that in this case 
that TTM inhibited the copper-catalyzed autoxidation of 
lipoproteins, the formation of ALEs, and the activation 
of macrophages in the vascular wall; although this study 
did not involve diabetes, it is certain that the process con-
tributes to diabetic vascular disease. Although the effects 
of TETA on the levels of AGEs, ALEs, or PrOPs in vascular 
tissue have not been systematically measured, it is clear 
that this simple chelator, which does not affect blood 
pressure or blood glucose concentration, may have poten-
tial use in diabetes therapy.
TETA and TTM are highly specific copper chelators. 
Why should chelation of copper alone have such a sig-
nificant impact in diabetes? Patients with Wilson disease 
do not develop classic diabetic complications, and iron, 
rather than copper, overload is more commonly associ-
ated with the onset and complications of diabetes [25, 26] 
as wells as atherosclerosis [27, 28] and neurodegenerative 
diseases [29, 30]. There is little information on the effec-
tiveness of iron chelation on the development of diabetes 
or its complications, except in iron overload diseases, but 
iron chelators have shown promise in the treatment of 
atherosclerosis [31, 32] and neurodegenerative disease [33, 
34]. Although iron chelators are not yet commonly used for 
the clinical management of these diseases, it seems that 
both iron and copper homeostasis are altered in concert 
in chronic diseases with an inflammatory component 
[35, 36], but, as developed below, targeting copper alone 
seems to be sufficient for controlling oxidative damage in 
tissues.
Brewer [37, 38] has summarized the evidence for the 
role of inorganic copper in the pathogenesis of age-related 
diseases, including diabetes, atherosclerosis, Alzhei-
mer disease, and other neurodegenerative diseases. In 
his discussion, he noted other earlier works [39–41] that 
observed the development of neurodegenerative disease 
in rabbits provided with tap water, but not in rabbits given 
distilled water to drink; those studies [39–41] eventu-
ally determined that the neurodegenerative disease was 
dependent on the copper concentration in the tap water 
[39, 40], exacerbated by a diet rich in saturated fats [41]. 
Based on this and other works, Brewer hypothesized that 
the increase in Alzheimer disease in the Western world 
results from the introduction of copper plumbing in the 
early 20th century. Supporting evidence for the central 
role of copper includes studies with zinc supplementa-
tion, which interferes with copper absorption from the 
intestines, and TTM protection against neurodegenerative 
disease in animal models [37, 38]. However, studies on the 
impact of dietary copper on neurodegenerative diseases 
in humans are less convincing [42, 43], suggesting that it is 
Table 1 Effect of copper on rate of oxidation of iron.
pH [Cu2+], μM Fe+2 half-life, min k1, min-1
6.56 0  > 120  < 0.01
6.82 0 30 0.023
6.94 0 12 0.058
7.02 0 8 0.086
7.24 0 4 0.17
6.0 0  > > 1200  < < 0.001
6.0 0.3 110 0.0063
6.0 3 60 0.012
6.0 30 40 0.017
6.0 150 20 0.035
The rate of autoxidation of ferrous (Fe+2) ion in aqueous buffer is 
first order in Fe+2 concentration (data not shown). The half-life of 
Fe+2 decreased, and the corresponding first-order rate constant for 
iron oxidation increased, with increasing pH (top) and with Cu2+ 
concentration (bottom). Reaction conditions: initial [Fe+2] = 36 μM, 
T = 20.5°C, pO2 = ambient, k1 = first-order rate constant for iron  
oxidation. Data adapted from Howells et al. [51].
not copper alone, but other factors in the diet or dysregu-
lation of the metabolism of copper (and/or other metals) 
that are the source of pathology. Similarly, it is possible 
that altered copper homeostasis, in concert with hyper-
glycemia and dyslipidemia of β-amyloid deposition, may 
also underlie the progression of tissue damage in diabe-
tes, atherosclerosis, and cardiovascular disease.
Hypothesis
A standard assay for the copper concentration in buffer 
solutions measures its activity as a catalyst of oxidation 
of ascorbic acid [44]. The half-life of ascorbic acid is mea-
sured in days in a metal-free buffer or in the presence of 
strong chelators, such as EDTA. However, the addition of 
micromolar concentrations of copper decreases the half-
life of ascorbate to a matter of minutes. In the presence 
of protein, this reaction leads to chemical modification, 
cross-linking, and browning of the protein by Maillard 
reactions [45]. Iron also catalyzes ascorbate oxidation, 
yielding ROS by redox cycling reactions under air. Uden-
friend and colleagues [46, 47] used this reaction for the 
hydroxylation of aromatic compounds, and Stadtman 
and colleagues [48, 49] showed that iron-catalyzed ascor-
bate oxidation was a source of AGEs, ALEs, and PrOPs in 
proteins.
Stumm and Lee [50] (Table 1) demonstrated that 
copper is a potent catalyst of autoxidation of iron, illus-
trating the interplay between the redox chemistry of these 
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metals. In an aqueous buffer at neutral pH, cupric (Cu+2) 
ion reacts with ferrous (Fe+2) iron to form cuprous (Cu+) 
and ferric (Fe+3) ions. Cu+ is then spontaneously reoxi-
dized to Cu+2 under air, continuing the catalytic cycle, 
while Fe+3 is unstable in an aqueous solution at physio-
logical pH, leading to its precipitation from the solution. 
To explain the effects of copper and iron chelators alone 
on chronic diseases, we propose that the copper-catalyzed 
oxidation of iron is responsible for the accumulation of 
iron in the vascular wall or neuronal plaque (Figure 1), 
where it serves as a local catalyst of Fenton reactions. 
These metal-catalyzed, nonenzymatic autoxidation reac-
tions are a source of ROS, including superoxide, peroxide, 
hydroxyl radicals, and reactive iron-oxo complexes in the 
extracellular space, contributing to local oxidative stress, 
protein chemical modification, and inflammation. Not all 
damage is oxidative, but oxidation dominates the profile 
of damage; oxidation products include numerous reactive 
carbonyl and peroxyl species and are clearly recognized 
by scavenger receptors.
In vivo, it seems likely that chelatable copper is bound 
loosely to AGEs in the vascular wall or neuronal plaque. 
Eaton, Monnier, and colleagues [52, 53] have shown that 
AGE proteins, particularly those containing the AGE Nε-
(carboxymethyl)lysine (CML), bind copper in a catalyti-
cally active form. Based on their structures, it seems likely 
that other AGE adducts and cross-links in protein, through 
their amino, carboxyl, hydroxyl, and carbonyl groups, 
may also have a metal-binding activity. The binding may 
be weak, but weak binding, without the occupation of all 
of the metal coordination sites, may in fact activate the 








Figure 1 Proposed scheme for the role of decompartmentalized 
copper in the production of ROS in the vascular wall and in neurode-
generative plaque.
Cu+2 is weakly bound in a redox-active form by tissue AGEs or 
β-amyloid protein, where it catalyzes the oxidation of Fe+2 to Fe+3, 
which precipitates from solution. The reoxidation of Cu+ generates 
ROS: hydroxyl radical, superoxide radical anion, and hydrogen  
peroxide. Shaded region: plasma membrane or extracellular matrix.
as outlined in Figure 1. Analogous to the binding of copper 
to AGEs in the vascular wall and extracellular matrix in 
diabetes and atherosclerosis, copper also binds strongly 
to β-amyloid proteins in neuronal plaques and in a redox-
active, catalytically active, ROS-generating form [51, 54]. 
The catalytic role of copper explains the effect of copper 
chelators alone in treatment of diabetes, atherosclerosis, 
and neurodegenerative disease and also the enrichment 
of iron in atherosclerotic and neurodegenerative plaque.
Clinical laboratory assessment of 
transition metal ion homeostasis
Oxidative stress is determined by the balance between 
the rate of generation of ROS and the efficiency of their 
trapping by antioxidant systems. There are three aspects 
to this equation, the rate of generation of ROS, the level 
of antioxidant defenses, and the net damage to tissues, 
assessed by the measurement of AGEs, ALEs, or PrOPs. 
Accurate measurement of the latter compounds requires 
sophisticated and expensive GC- or LC-MS/MS analysis, 
which is not readily conducted in most clinical chemistry 
laboratories. A number of assays have been developed for 
measuring the antioxidant or radical trapping capacity 
of plasma [55, 56], typically using an oxidant-generating 
probe and measuring the radical-reducing or radical-
scavenging activity of plasma. The rate at which ROS are 
generated in plasma is less commonly measured, in part 
because the rate of generation of ROS is low and in part 
because of the efficient quenching of ROS in plasma. For 
this reason, it has been difficult to quantify the activity of 
metal ion catalysts in plasma and the extravascular space. 
At the same time, the evidence is clear that, based on the 
effects of chelators and other drugs with chelating activ-
ity, decompartmentalized, free metal ions are central to 
the development of tissue damage in chronic, age-related 
diseases. It is not the absolute concentration of these ions 
but their catalytic activity that is relevant – and, unfortu-
nately, difficult to measure.
Blood plasma permeates the extravascular space and 
the free metal ion concentration in plasma (or cerebrospi-
nal fluid in the case of neurodegenerative diseases) is con-
sidered to be in equilibrium with that in the vascular wall 
and extracellular matrix. Thus, the measurement of free 
iron and copper in plasma could provide some insight into 
tissue-bound metal and the level of exposure to ROS gen-
eration by these catalytic metal ions. However, the mea-
surement of plasma free iron and copper are not simple 
procedures in the clinical laboratory. The measurement 
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of plasma iron status requires the analysis of total iron, 
transferrin, ferritin, and iron-binding capacity. Because 
transferrin and ferritin bind iron with high affinity and 
Fe+3 precipitates spontaneously from physiological solu-
tions, there is but a negligible fraction of free iron in 
plasma. Plasma free copper is estimated as the difference 
between total copper less ceruloplasmin copper. Because 
approximately 90% of plasma copper is bound to cerulo-
plasmin, this assay is based on the difference between two 
large numbers. McMillin et al. [57] have recently reviewed 
the limitations of this assay, noting that it is “unreliable 
and insensitive”, yielding “mathematically negative and 
elevated results in the vast majority of healthy people”. 
These authors also describe a more rigorous assay, using 
ICP-MS to measure free copper in a plasma ultrafiltrate. 
Still, these assays provide no indication of the redox acti-
vity of the iron or copper in the circulation, i.e., the frac-
tion that functions as catalyst of autoxidation reactions. 
Considering that iron and copper work in concert to cata-
lyze these reactions, the measurement of either ion alone 
may provide limited insight into the catalytic activity of 
plasma, whereas the results of measurement of both may 
be difficult to interpret. The interpretation may be further 
complicated by the presence of other metal ions (such as 
zinc and manganese), amino acids (such as cysteine and 
histidine), or proteins (such as albumin), which alter the 
activity of copper and iron in autoxidation reactions.
What is needed for the assessment of plasma redox 
metal ion homeostasis is an assay of plasma autoxidative 
catalytic activity (PACA), i.e., the net rate of catalysis of 
autoxidation reactions and formation of ROS, using a rele-
vant substrate in the plasma. One approach to this assay 
is to measure the steady-state rate of formation of a gly-
coxidation product, such as CML or pentosidine, during 
the incubation of plasma in vitro. The kinetics may be 
complicated by an early stage during which endogenous 
antioxidants are consumed, but the rate should stabilize 
thereafter. An assay of this type has been described by 
Miyata et al. [58], who measured the rate of AGE formation 
in control and uremic plasma. Based on this assay, PACA 
was increased by approximately 150% in plasma from 
nondiabetic, uremic subjects, compared with controls. 
However, the assay involved several weeks’ incubation of 
plasma at 37°C, followed by acid hydrolysis of proteins and 
HPLC analysis of pentosidine, a fluorescent Maillard reac-
tion cross-link in proteins. Although the analysis of pen-
tosidine is not readily performed in a clinical laboratory, 
CML, another glycoxidation product formed in this incu-
bation, might be measured more conveniently by ELISA. 
The major limitation of the assay, however, it that many 
artifacts may develop during a multiweek incubation of 
plasma, including protein denaturation and precipitation 
and release of copper and iron from plasma proteins (ceru-
loplasmin, ferritin, transferrin, and others). However, 
the concept is valuable: this PACA assay does provide a 
measure of the rate of metal-catalyzed autoxidation reac-
tions. Miyata et al. [59] also observed a 2.5-fold increase in 
the dehydroascorbate/ascorbate ratio in uremic plasma, 
which correlated significantly with both free and protein-
linked pentosidine concentration in plasma, suggesting 
that ascorbate autoxidation was a possible source of the 
increase in plasma pentosidine in uremia.
It should be possible to increase the sensitivity of 
this PACA assay and minimize artifacts by the addition 
of a fixed concentration of ascorbate, which is autoxi-
dized  > 1000-fold more rapidly than glucose and is 10–100 
times more reactive in the formation of AGEs, compared 
with glucose [59, 60]. The assay might also be simplified 
by measuring the changes in total Maillard reaction flu-
orescence instead of pentosidine alone. An assay of this 
type, with an appropriate anaerobic control for the non-
oxidative generation of fluorophores, should be adaptable 
to a high-throughput microplate reader. Such an assay 
should yield a useful index of the activity of plasma metal 
ion catalytic activity, rather than metal ion concentra-
tion, providing a measure of exposure of the vasculature 
to oxidative stress. The analysis of PACA in the presence 
of iron- or copper-specific chelators, such as desferriox-
amine or TETA may also provide insight into the relative 
role of these metals in plasma autoxidation reactions. The 
clinical merits of the assay could be assessed by the com-
parison of the catalytic activity in the plasma of control 
and diabetic patients and in diabetic patients with renal 
and/or vascular complications. The analysis of plasma 
from diabetic patients on various drug therapies might 
also provide an index of the efficiency of various antihy-
pertensive and antidiabetic agents, in most cases, chela-
tors as inhibitors of PACA. Overall, the PACA assay would 
complete the loop describing the status of oxidative stress 
in plasma, providing an assessment of the rate of genera-
tion of ROS to complement the current measures of oxida-
tive damage and antioxidant capacity.
Summary
In this article, we have briefly summarized the evidence 
of the involvement of free copper and iron in the devel-
opment of pathology in three chronic, age-related dis-
eases: diabetes, atherosclerosis, and neurodegenerative 
diseases. We have proposed a special role for copper as 
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a catalyst of iron oxidation and deposition in tissues and, 
jointly with iron, a role in the production of ROS and a pro-
inflammatory environment in renal, vascular, and neural 
tissue. We also proposed the development of a method to 
assess the overall metal-dependent autoxidative activity 
of plasma, based on the autoxidation of ascorbate. With 
a better understanding of transition metal homeostasis 
in plasma and cerebrospinal fluid, it may be possible to 
develop more effective therapies targeted at the control of 
oxidative stress and inflammation in chronic diseases.
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